- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of May 14
The Center for Biosimilars® recaps the top 5 articles for the week of May 14, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 14.
Number 5: The President’s plan to reduce drug prices for Americans includes asking FDA to issue guidance on possible abuse of safety programs to delay generic or biosimilar competition.
Number 4: Pfenex has announced positive top-line results from a phase 3 study of its follow-on teriparatide, referencing Forteo, a recombinant human parathyroid hormone.
Number 3: A study of pregnant patients treated with biosimilar infliximab for inflammatory bowel disease found that the biosimilar was not associated with any new safety concerns.
Number 2: CMS has released updated versions of its Drug Spending Dashboards, and data included show that prices are on the rise for drugs that have existing or upcoming biosimilar competition.
Number 1: The FDA has approved Pfizer’s epoetin alfa biosimilar, Retacrit, which the company is preparing to launch in 2018.
Finally, last week, our e-newsletter asked for your thoughts on which approach to biosimilar education is likely to have the biggest impact.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
